

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Proposed Single Technology Appraisal**

**Nintedanib for treating progressive fibrosing interstitial lung disease  
ID1599**

**Provisional stakeholder list of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Boehringer Ingelheim (nintedanib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action for Pulmonary Fibrosis</li> <li>• British Lung Foundation</li> <li>• Muslim Council of Britain</li> <li>• NARA – The Breathing Charity</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• The Pulmonary Fibrosis Trust</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association for Respiratory Technology and Physiology</li> <li>• Association of Respiratory Nurse Specialists</li> <li>• British Geriatrics Society</li> <li>• British Thoracic Society</li> <li>• National Heart and Lung Institute</li> <li>• Primary Care Respiratory Society UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Herts Valleys CCG</li> <li>• NHS North Norfolk CCG</li> <li>• Welsh Government</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (mycophenolate)</li> <li>• Accord-UK (prednisolone, azathioprine, mycophenolate)</li> <li>• ADVANZ Pharma (prednisolone)</li> <li>• Alliance Pharmaceuticals (prednisolone)</li> <li>• Aspen (azathioprine)</li> <li>• Baxter Healthcare (cyclophosphamide)</li> <li>• Biogen Biosimilars (infliximab)</li> <li>• Ennogen Pharma (azathioprine)</li> <li>• Generics UK t/a Mylan (azathioprine)</li> <li>• Logixx Pharma Solutions (prednisolone)</li> <li>• Merck Sharp &amp; Dohme (infliximab)</li> <li>• Napp Pharmaceuticals (infliximab, rituximab)</li> </ul>

Provisional stakeholder list for the proposed technology appraisal of nintedanib for treating progressive fibrosing interstitial lung disease ID1599. Issue date: September 019

## Appendix C

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> <li>• Novartis Pharmaceuticals UK (mycophenolate)</li> <li>• Pfizer (infliximab)</li> <li>• Roche Products (mycophenolate rituximab)</li> <li>• Sandoz (cyclophosphamide, infliximab, mycophenolate, rituximab)</li> <li>• Teva Pharma (mycophenolate)</li> <li>• Wockhardt UK (prednisolone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Breathing Matters</li> <li>• British Association for Lung Research</li> <li>• Cochrane Airways Group</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.